TB Alternative Assets Increases Stake in Moderna

Summary

TB Alternative Assets Ltd. increased its stake in Moderna, Inc. (NASDAQ:MRNA) by 93.3% in Q2, now holding 1,260,953 shares, making it the 8th largest position in their portfolio. Other investors like Invesco and UBS also raised their holdings. Moderna’s stock has a consensus rating of ‘Hold’ with a target price of $41.81. The company reported a quarterly EPS of ($2.13), exceeding estimates, but revenue fell 41.1% year-over-year. Moderna’s market cap is $10.07 billion, with shares trading at $25.88.Market Beat

Impact Analysis

So basically, TB Alternative Assets is doubling down on Moderna despite its revenue dropping 41.1% year-over-year and a quarterly EPS loss of $2.13, which still beat estimates.Market Beat This move suggests a strong belief in Moderna’s long-term potential, possibly driven by its expanding pipeline in vaccines for flu, RSV, and cancer.MSN The stock’s technical indicators are mixed, with a long-term downtrend but a short-term potential for rebound as it nears the lower Bollinger Band. The market seems focused on the immediate financial struggles, but TB’s increased stake could indicate undervaluation, especially with Moderna’s strategic expansions and international agreements expected to boost revenue significantly by 2026.Tip Ranks The trade here might be to watch for a sentiment shift as more institutional investors increase their holdings, potentially driving the stock price up from its current lows.